<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/25/ocular-therapeutix-ocul-investment-analysts-weekly-ratings-updates.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-25T09:33:55+00:00"/>
    <meta property="og:title" content="Ocular Therapeutix (OCUL) – Investment Analysts’ Weekly Ratings Updates"/>
    <meta property="og:description" content="Several brokerages have updated their recommendations and price targets on shares of Ocular Therapeutix (NASDAQ: OCUL) in the last few weeks: 11/15/2019 – Ocular Therapeutix was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on […]"/>
  </head>
  <body>
    <article>
      <h1>Ocular Therapeutix (OCUL) – Investment Analysts’ Weekly Ratings Updates</h1>
      <address><time datetime="2019-11-25T09:33:55+00:00">25 Nov 2019, 09:33</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/ocular-therapeutix-inc-logo.png"/>
      </figure>
      <p>Several brokerages have updated their recommendations and price targets on shares of <b>Ocular Therapeutix</b> (NASDAQ: OCUL) in the last few weeks:</p>
      <ul>
        <li>11/15/2019 – Ocular Therapeutix was upgraded by analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> from a “sell” rating to a “hold” rating. According to Zacks, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. “</li>
        <li>11/15/2019 – Ocular Therapeutix had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock, down previously from $9.00.</li>
        <li>11/13/2019 – Ocular Therapeutix had its price target lowered by analysts at JMP Securities from $9.00 to $7.00. They now have a “market outperform” rating on the stock.</li>
        <li>11/12/2019 – Ocular Therapeutix had its price target lowered by analysts at Piper Jaffray Companies from $8.00 to $5.00. They now have an “overweight” rating on the stock.</li>
        <li>10/18/2019 – Ocular Therapeutix had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.</li>
      </ul>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/OCUL/price-target/">OCUL stock</a> opened at $3.17 on Monday. The firm has a fifty day moving average price of $3.17 and a 200 day moving average price of $3.87. Ocular Therapeutix Inc has a fifty-two week low of $2.35 and a fifty-two week high of $6.88. The company has a debt-to-equity ratio of 5.07, a quick ratio of 6.25 and a current ratio of 6.33. The firm has a market cap of $141.84 million, a PE ratio of -2.02 and a beta of 2.13.</p>
      <p>Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.01. The company had revenue of $0.83 million during the quarter, compared to analyst estimates of $1.09 million. Ocular Therapeutix had a negative net margin of 3,141.58% and a negative return on equity of 383.58%. On average, equities analysts predict that Ocular Therapeutix Inc will post -1.72 EPS for the current year.</p>
      <p>Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new position in Ocular Therapeutix during the third quarter worth $32,000. Creative Planning purchased a new position in Ocular Therapeutix during the second quarter worth $52,000. Clear Harbor Asset Management LLC purchased a new position in Ocular Therapeutix during the third quarter worth $38,000. Highland Capital Management LLC purchased a new position in Ocular Therapeutix during the second quarter worth $62,000. Finally, Sio Capital Management LLC purchased a new position in Ocular Therapeutix during the second quarter worth $263,000. 49.81% of the stock is owned by institutional investors.</p>
      <p>Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.</p>
      <p>See Also: <a href="https://www.marketbeat.com/dividends/monthly-dividend-payers/">Monthly Dividend Stocks Can Provide Solid Income</a></p>
    </article>
  </body>
</html>